Seasoned finance leader to support Norstella’s next phase of growth
New York, New York – Sept. 9, 2025 – Norstella, a leading global provider of pharma intelligence solutions, has appointed Dan Tempesta as its new Chief Financial Officer. This marks an exciting milestone in Norstella’s journey and underscores the company’s commitment to its next phase of growth.
“Norstella has built a remarkable foundation as a trusted partner in the life sciences industry, and I can’t wait to help build on this momentum,” Tempesta said. “This is an organization with a mission that matters: helping improve access to life-saving treatments. It’s clear to me that the commitment and drive of the people here are what continue to create value for clients, patients, and industry stakeholders.”
Tempesta brings over three decades of experience in finance leadership across technology, software, cloud, AI, and healthcare industries. Most recently, he served as CFO and Executive Vice President at Nuance Communications, where he played an instrumental role in the company’s transformation and led efforts culminating in Nuance’s $20 billion acquisition by Microsoft. Tempesta possesses deep expertise in B2B software and has a proven track record in merger and acquisition strategy, operational finance, business model transformation, and building high-performing global finance teams.
“Dan is joining us at a pivotal inflection point for our organization,” said Norstella CEO Kris Joshi. “His deep experience, expertise and leadership skills will be critical as we continue to evolve and help pharma companies bring life-changing therapies to market faster.”
For more information, visit norstella.com.
About Norstella
Our mission is simple: to smooth the path to lifesaving therapies for patients and providers. Norstella consists of prominent pharmaceutical solutions providers that have joined forces to offer a full range of consultancy services and solutions. Through its brands—Citeline, Evaluate, MMIT, Panalgo and The Dedham Group—Norstella supports biopharma companies in making smarter, faster decisions across the drug development and commercialization lifecycle. For more information visit Norstella and follow us on LinkedIn.